Evelo Biosciences Inc logo

EVLO

Evelo Biosciences Inc

$2.65

Earnings Summary

Revenue
$0Mn
Net Profits
$-29.86Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Evelo Biosciences Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Evelo Biosciences Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Evelo Biosciences Inc’s net profit fell -5.91% since last year same period to $-29.86Mn in the Q1 2022. On a quarterly growth basis, Evelo Biosciences Inc has generated -4.22% fall in its net profits since last 3-months.

Net Profit Margins:

Evelo Biosciences Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Evelo Biosciences Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Evelo Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.43
EPS Estimate Current Year
-0.43

Highlights

EPS Estimate Current Quarter:

Evelo Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.43 - a 25.86% jump from last quarter’s estimates.

EPS Estimate Current Year:

Evelo Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.43.

Key Ratios

Key ratios of the Evelo Biosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.56
Return on Assets (ROA)
-0.58
Return on Equity (ROE)
-2.51
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Evelo Biosciences Inc’s earning per share (EPS) fell -1.82% since last year same period to -0.56 in the Q1 2022. This indicates that the Evelo Biosciences Inc has generated -1.82% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Evelo Biosciences Inc’s return on assets (ROA) stands at -0.58.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Evelo Biosciences Inc’s return on equity (ROE) stands at -2.51.

Dividend Per Share (DPS):

Evelo Biosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.58
-0.56
3.45%

Company Information

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Organisation
Evelo Biosciences Inc
Employees
2.02K
Industry
Health Technology